Predictmedix Introduces Ground-breaking Technology for Cardiovascular Risk Management: Safe Entry Stations Now Measure Blood Pressure, Heart Rate Variability and Blood Oxygen Non-Invasively

TORONTO, ON / April 19, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), is proud to announce a significant advancement in its Safe Entry Stations. The Company's AI-powered screening technology will now be able to take non-invasive blood pressure readings, making Safe Entry a vital tool for detecting and managing cardiovascular diseases, the leading cause of global mortality.

Using artificial intelligence technology, Predictmedix's Safe Entry Stations already screen individuals for vital parameters such as temperature, heart rate, respiratory rate, and oxygen saturation. With the added ability to measure systolic and diastolic blood pressure, Safe Entry Stations now provide even greater accuracy for its healthcare applications as well as workplace and law enforcement screening tools.

"Monitoring blood pressure is an essential aspect of maintaining good health. Adding this feature to Safe Entry will be a significant development in the healthcare industry," said Dr. Rahul Kushwah, Chief Operations Officer at Predictmedix. "By incorporating blood pressure parameters into our screening process, we can help make healthcare screening more accessible and efficient for patients."

Predictmedix is also pleased to announce that it has introduced Heart Rate Variability (HRV) in its vital parameters detection, which provides an early indication of the onset of several diseases. The HRV component reflects the functions of a parasympathetic and sympathetic nervous system, the two components of the Autonomic Nervous System (ANS), which control heart activity. Studies are underway in India to progress and validate HRV screening capabilities. Additionally, the company is initiating Blood Oxygen Saturation screening trials to further enhance its screening solutions.

"With the addition of HRV, blood oxygen saturation, and blood pressure readings, Predictmedix's Safe Entry Stations take us into a new frontier of what is possible for healthcare and other industries alike," said Kushwah. "We're proud to be at the forefront of AI-based screening solutions and are committed to continuing to provide innovative technology to help keep people safe and healthy."

"We are committed to continuously expanding our AI screening solutions to bring added value and greater efficiencies to healthcare risk management. It was a pleasure to host government officials and technologists from a major global economy over the past two weeks, who are exploring various ways to make AI-powered health screening commonplace and establish it as the standard of care. We are excited to collaborate with like-minded individuals and organizations to make healthcare more accessible and efficient for all," concluded Kushwah.

About Predictmedix Inc.

Predictmedix (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes
Hudes Communications International
(905) 660 9155
Nelson@hudescommunications.com

Dr. Rahul Kushwah
(647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors

beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: PredictMedix Inc.